Perspective Therapeutics, Inc.
CATX evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $320.8M
- Lead Asset:
- PSV359 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for CATX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CATX
Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies using Lead-212 for multiple oncology indications, with a lead program advancing toward Phase 3.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$320.8M
Cash Runway
—
Lead Asset
PSV359 (Phase 1/Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Perspective Therapeutics, Inc..
Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies using Lead-212 for multiple oncology indications, with a lead program advancing toward Phase 3.
- Cash, cash equivalents, and short-term investments were approximately $237 million as of June 3, 2026 [news].
- Net income was -$26.8M and shareholders' equity was $323.9M as of 2026-06-30 [sec].
- Lead program VMT-α-NET is advancing toward a Phase 3 study in neuroendocrine tumors, with clinical site activation targeted around year-end 2026 subject to regulatory feedback [news].
- Announced a clinical collaboration with Merck to evaluate [212Pb]PSV359 in combination with Keytruda in FAP-α positive solid tumors [news].
- The company has not generated revenue from product sales other than its discontinued brachytherapy business and has incurred significant net losses [sec_mda].
What works
- Strong cash position of approximately $237 million as of June 3, 2026 provides runway to fund clinical milestones into late 2027 [news][sec_mda].
- Proprietary Lead-212 alpha-emitting platform enables a theranostic approach that may improve efficacy and minimize toxicity [sec_mda].
- Multiple clinical-stage programs (VMT-α-NET, VMT01, PSV359) diversify pipeline risk and target different tumor types [pipeline][news].
- Clinical collaboration with Merck for PSV359 plus Keytruda adds validation and potential combination therapy upside [news].
What to weigh
- No regulatory approval for any current product candidate; the company has not generated revenue from product sales other than its discontinued brachytherapy business [sec_mda].
- Recurring net losses, with a net loss of -$26.8M reported as of 2026-06-30 [sec].
- Expenses are expected to increase as clinical programs advance, requiring continued capital and no guarantee of future funding [sec_mda].
- VMT-α-NET faces competition from Lutathera (Novartis) in the neuroendocrine tumor space [pipeline].
From the filings
Quoted directly from source documents.
Cash position as of June 3, 2026
“Approximately $237 million in cash, cash equivalents, and short-term investments as of June 3”
News · August 10, 2026
No revenue from product sales other than discontinued brachytherapy business
“have not generated any revenue from product sales other than our discontinued brachytherapy business and have incurred significant net losses”
SEC MD&A · March 16, 2026
VMT-α-NET Phase 3 planning
“Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback”
News · August 10, 2026
Catalyst timeline
- 2023-06-01 · Phase 2 start for VMT01 melanoma study — First-in-human study of [212Pb]VMT01 in melanoma initiated.
- 2023-09-27 · Phase 2 start for VMT-α-NET NET study — First-in-human study of [212Pb]VMT-α-NET in SSTR2-positive tumors initiated.
- 2025-04-28 · Phase 2 start for PSV359 FAP study — First-in-human study of [203/212Pb]PSV359 in FAP-positive solid tumors initiated.
Risks & what to watch (4)›
Key risks
- No approved products — No regulatory approval for any current product candidate; no revenue from product sales other than discontinued brachytherapy [sec_mda].
- Recurring net losses — Net loss of -$26.8M as of 2026-06-30; expenses expected to increase with clinical advancement [sec][sec_mda].
- Competition in NET space — VMT-α-NET competes with Lutathera (Novartis) in neuroendocrine tumors [pipeline].
- Dependence on future capital — Company has limited operating history and may need additional capital to fund operations beyond late 2027 [sec_mda].
What to watch
- Regulatory alignment and clinical site activation for VMT-α-NET Phase 3 study, targeted around year-end 2026 [news].
- Oral presentation of VMT-α-NET study update at ESMO 2026 [news].
- Progress of the Merck collaboration for PSV359 plus Keytruda in FAP-α positive solid tumors [news].
- Cash burn rate and any future capital raises as expenses increase [sec_mda].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Perspective Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Perspective Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.21 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
136
Total value held
$350.7M
| Holder | Shares | Value |
|---|---|---|
| avidity partners management lp | 12,099,998 | $48.8M |
| tcg crossover management, llc | 7,915,567 | $33.0M |
| commodore capital lp | 6,336,782 | $26.4M |
| blackrock, inc. | 5,348,561 | $22.3M |
| opaleye management inc. | 4,675,000 | $19.5M |
| vanguard capital management llc | 4,378,956 | $18.3M |
| millennium management llc | 4,046,640 | $16.9M |
| citadel advisors llc | 3,566,504 | $14.9M |
| affinity asset advisors, llc | 3,164,582 | $13.2M |
| state street corp | 3,132,670 | $13.1M |
Showing top 10 of 136 institutional holders of Perspective Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 13.6%
- Days to cover
- 11.1
- Shares short
- 12,997,351
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CATX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Perspective Therapeutics, Inc.?
Perspective Therapeutics (CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies using Lead-212 for multiple oncology indications, with a lead program advancing toward Phase 3.
What is Perspective Therapeutics, Inc.'s lead drug candidate?
Perspective Therapeutics, Inc.'s most advanced tracked candidate is PSV359 (Phase 1/Phase 2) for Pancreatic Ductal Adenocarcinoma.
Who is the CEO of Perspective Therapeutics, Inc.?
Mr. Johan M. Spoor is the chief executive officer of Perspective Therapeutics, Inc. (CATX).
Where is Perspective Therapeutics, Inc. headquartered?
Perspective Therapeutics, Inc. (CATX) is headquartered in Seattle, WA, United States.
What therapeutic areas does Perspective Therapeutics, Inc. focus on?
Perspective Therapeutics, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.